Advertisement

Topics

Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia

16:00 EDT 29 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
— Once-Daily, Oral Product Candidate Demonstrated Antipsychotic Efficacy Statistically Superior to Placebo and Similar to Olanzapine in ENLIGHTEN-1 Study — — Management to Hold Conference Call Today at 4:30 p.m. E...

Other Sources for this Article

Alkermes plc
For Investors:
Eva Stroynowski, +1 781-609-6823
or
Sandy Coombs, +1 781-609-6377
or
For Media:
Jennifer Snyder, +1 781-609-6166

NEXT ARTICLE

More From BioPortfolio on "Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Schizophrenia
Schizophrenia is a common  serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...